Goal 2: Reduce Human Disease

Clinical trial of AAT augmentation therapy in PI MZ subjects

Although severely alpha-1 antitrypsin deficiency (PI ZZ) individuals are rare, PI MZ subjects comprise approximately 3% of the US population. Mounting evidence suggests that PI MZ is a significant risk factor for COPD. A clinical trial of COPD exacerbation frequency using AAT augmentation therapy in PI MZ subjects with moderate-to-severe COPD could provide a rationale for AAT augmentation therapy (or small molecule neutrophil ...more »

Submitted by (@nhlbiforumadministrator)

Voting

1 net vote
1 up votes
0 down votes
Active

Goal 2: Reduce Human Disease

Study of Prevention of Airflow Obstruction Progression

There should be a study for prevention of Airflow Obstruction Progression. Rationale: All diseases have a prodrome followed by an early face of disease progression. Complex medical chronic diseases can only be slowed through the addition of several interventions all of which contribute to a final improvement of prognosis (witness CV diseases). Definition of “Early Disease”: Would be aimed at patients with airflow obstruction ...more »

Submitted by (@nhlbiforumadministrator)

Voting

1 net vote
1 up votes
0 down votes
Active

Goal 3: Advance Translational Research

Implementation of checklist to improve outcomes of COPD patients with acute exacerbations

Implementation of checklist to improve outcomes of COPD patients with acute exacerbations

 

• Does implementation of a checklist designed to improve the care of patients with COPD exacerbations result in greater adherence to guideline recommendations?

 

• Does implementation of a checklist designed to improve the care of patients with  COPD exacerbations results in improved patient outcomes?

Submitted by (@nhlbiforumadministrator)

Voting

3 net votes
3 up votes
0 down votes
Active

Goal 1: Promote Human Health

THE RELEVANCE OF PREVENTION TRIALS

Prevention trials, implemented to reduce or delay progression to overt disease in a population at risk to the disease, are an important approach to health promotion. Therapies shown to reduce disease severity in patients with a specific disease are obvious, but not the only, candidates for a prevention trial in populations at high risk for prevalent diseases (such as heart failure, diabetes, COPD, asthma in children). ...more »

Submitted by (@media0)

Voting

7 net votes
10 up votes
3 down votes
Active

Goal 2: Reduce Human Disease

How can we better understand regional tissue heterogeneity in lung disease?

Many lung diseases (IPF, COPD) are characterized by marked heterogeneity at the tissue level. Unfortunately, most of the tools we currently employ to understand lung disease are unable to elucidate the mechanisms that result in regional heterogeneity. Clinical studies and animal models, while invaluable, generally assume that all lung tissue is similarly affected based on the presence or absence of diagnostic criteria ...more »

Submitted by (@bradley.richmond)

Voting

9 net votes
26 up votes
17 down votes
Active